Yahoo Finance
Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting
Dec 16, 2021·3 min read
TAIPEI and SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting preliminary clinical data for their lead drug candidate, Silmitasertib (CX-4945), in patients with advanced Basal Cell Carcinoma (BCC), has been accepted for e-poster with an oral presentation at the upcoming 2022 American Academy of Dermatology (AAD) annual meeting in Boston, Massachusetts, held from March 25-29, 2022.
Presentation title, date and time are as follows:
Title: A Phase 1 study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma.
Session: Poster Presentation Center 1 in the Exhibit Hall
Date: March 27, 2022
Time: 8:30 am – 8:35 am
The American Academy of Dermatology is the largest, most influential, and representative dermatology group in the United States. The poster presentation will feature new findings on disease control from a phase 1 study evaluating safety and efficacy of Silmitasertib in patients with advanced BCC.
BCC is the most common type of skin cancer. In the United States, the annual incidence of newly diagnosed BCC is about 4.3 million with approximately 3,000 people dying from BCC annually. Most basal cell carcinomas can be surgically removed; however, for unresectable tumors there are two approved targeted drugs and both are characterized as smoothened inhibitors (SMOi).
SMOi targeting the Hedgehog (Hh) pathway and have been approved for the treatment of patients with locally advanced BCC (laBCC) or metastatic BCC (mBCC). Unfortunately, resistance against SMOi can develop. Targeting the signaling cascade downstream of SMOi could avoid this issue. Casein Kinase 2 (CK2) affects the terminal component of the Hh signaling pathway by promoting GLI-2 stability and GLI-2's interaction with target genes. Given the interplay between CK2 and GLI-2 and the importance of Hh signaling activation, Senhwa's Silmitasertib (CX-4945), a potent CK2 inhibitor, may provide benefits for BCC patients with SMOi resistant cancers.